(R)-5,7-Difluorochroman-4-ol CAS 1270294-05-7 Purity ≥99.0% (HPLC) Tegoprazan Side Chain Intermediate
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of (R)-5,7-Difluorochroman-4-ol (CAS: 1270294-05-7) with high quality, the key intermediate of Tegoprazan (CAS: 942195-55-3). Please contact:alvin@ruifuchem.com
Intermediates of Tegoprazan
Tegoprazan CAS: 942195-55-3
(R)-5,7-Difluorochroman-4-ol CAS: 1270294-05-7
4-Hydroxy-N,N,2-trimethyl-1-tosyl-1H-benzo[d]imidazole-6-carboxamide CAS: 942195-86-0
1-Benzyl-4-hydroxy-2-methyl-1H-benzo[d]imidazole-6-carboxylic acid CAS: 1640981-19-6
| Chemical Name | (R)-5,7-Difluorochroman-4-ol |
| Synonyms | Tegoprazan Side Chain; Tegoprazan Intermediate; Tegoprazan Impurities C; Tegoprazan Impurity 11 |
| CAS Number | 1270294-05-7 |
| Stock Status | In Stock, Commercial Production |
| Molecular Formula | C9H8F2O2 |
| Molecular Weight | 186.16 |
| Boiling Point | 228.4±40.0℃ (Predicted) |
| Density | 1.402±0.06 g/cm3(Predicted) |
| Storage Condition | Store at 2-8℃, away from light, inert gas |
| COA & MSDS | Available |
| Shipping Temperature | Normal |
| Origin of Product | Shanghai, China |
| Product Categories | Tegoprazan Intermediate |
| Brand | Ruifu Chemical |
| Item | Specifications | Results |
| Appearance | White to Off-White Powder | Conforms |
| 1 H NMR Spectrum | Consistent with structure | Conforms |
| Purity / Analysis Method | ≥99.0% (HPLC) | 99.9% |
| Total Impurities | ≤1.0% (HPLC) | 0.1% |
| Water (K.F) | ≤0.50% | 0.2% |
| Residue on Ignition | ≤0.20% | 0.08% |
| Test Standard | Enterprise Standard | Conforms |
Package: Fluorinated Bottle, 1kg/bag, 25kg/drum, or according to customer's requirement
Storage Condition:Store in sealed containers at cool and dry place (2-8℃); Protect from light and moisture.
Shipping: Deliver to worldwide by air, by sea, by FedEx / DHL Express. Provide fast and reliable delivery.
(R)-5,7-Difluorochroman-4-ol (CAS: 1270294-05-7), the key intermediate of Tegoprazan (CAS: 942195-55-3).
Tegoprazan was approved by the Ministry of Food and Drug Safety (MFDS) for marketing in July 2018 for the treatment of gastroesophageal reflux disease and erosive esophagitis. Tegoprazan was originally developed by Pfizer. In 2008, it was licensed to RaQualiaPharma (separated from Pfizer) for joint development. In 2014, Tegoprazan was licensed to CJHealthCare by RaQualiaPharma. Finally, CJHealthCare was successfully developed and marketed in Korea. The drug was first marketed in South Korea.
Tegoprazan is used for remedying and treating nocturnal acid breakthrough symptoms, such as GERD, ulcer, Barrett''s esophagus, and heartburn.
Intermediates of Tegoprazan
Tegoprazan CAS: 942195-55-3
(R)-5,7-Difluorochroman-4-ol CAS: 1270294-05-7
4-Hydroxy-N,N,2-trimethyl-1-tosyl-1H-benzo[d]imidazole-6-carboxamide CAS: 942195-86-0
1-Benzyl-4-hydroxy-2-methyl-1H-benzo[d]imidazole-6-carboxylic acid CAS: 1640981-19-6
